Payment overview · 2025
General Payments
$408.54
20 reported records · 10 companies
Healthcare provider profile · identity verified
Rupinder Mann, M D INC
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · RANCHO MIRAGE, CA · NPI 1982799813
Verified facts
What the public records show
CMS Open Payments records show Rupinder Mann, M D INC received $408.54 in general payments during 2025 across 20 reported records.
Amgen Inc. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.60 | 26.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.93 | 14.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.55 | 11.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.11 | 11.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.82 | 10.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.43 | 8.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.74 | 6.3% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.19 | 3.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.78 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.39 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $408.54 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.93 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $48.55 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 231 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 117 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
231 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
231 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
117 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 927 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 807 | 213 |
| Losartan Potassium | Losartan Potassium | 700 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 366 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 87 |
| Lisinopril | Lisinopril | 286 | 82 |
| Duloxetine Hcl | Duloxetine Hcl | 267 | 55 |
| Metformin Hcl | Metformin Hcl | 249 | 68 |
| Gabapentin | Gabapentin | 246 | 85 |
| Alprazolam | Alprazolam | 242 | 77 |
| Jardiance | Empagliflozin | 231 | 62 |
| Furosemide | Furosemide | 227 | 70 |
| Montelukast Sodium | Montelukast Sodium | 225 | 74 |
| Trazodone Hcl | Trazodone Hcl | 215 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 52 |
| Felodipine Er | Felodipine | 191 | 53 |
| Omeprazole | Omeprazole | 190 | 52 |
| Potassium Chloride | Potassium Chloride | 182 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 51 |
| Mirtazapine | Mirtazapine | 175 | 44 |
| Carvedilol | Carvedilol | 151 | 48 |
| Lorazepam | Lorazepam | 149 | 41 |
| Sertraline Hcl | Sertraline Hcl | 144 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 35 |
| Eliquis | Apixaban | 138 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 136 | 46 |
| Alendronate Sodium | Alendronate Sodium | 134 | 35 |
| Simvastatin | Simvastatin | 132 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 36 |
| Famotidine | Famotidine | 125 | 43 |
| Estradiol | Estradiol | 122 | 42 |
| Ezetimibe | Ezetimibe | 120 | 37 |
| Mounjaro | Tirzepatide | 117 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 27 |
| Calcitriol | Calcitriol | 93 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 42 |
| Finasteride | Finasteride | 90 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 26 |
| Donepezil Hcl | Donepezil Hcl | 82 | 24 |
| Buspirone Hcl | Buspirone Hcl | 78 | 17 |
| Allopurinol | Allopurinol | 76 | 23 |
| Trulicity | Dulaglutide | 75 | 15 |
| Memantine Hcl | Memantine Hcl | 74 | 17 |
| Ozempic | Semaglutide | 73 | 16 |
| Atenolol | Atenolol | 72 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 19 |
| Prednisone | Prednisone | 69 | 51 |
| Synthroid | Levothyroxine Sodium | 69 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Meloxicam | Meloxicam | 64 | 21 |
| Myrbetriq | Mirabegron | 64 | 22 |
| Bupropion Xl | Bupropion Hcl | 63 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 17 |
| Valacyclovir | Valacyclovir Hcl | 62 | 30 |
| Celecoxib | Celecoxib | 59 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 23 |
| Clonazepam | Clonazepam | 54 | 13 |
| Diazepam | Diazepam | 53 | 17 |
| Januvia | Sitagliptin Phosphate | 53 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 28 |
| Tramadol Hcl | Tramadol Hcl | 49 | 25 |
| Acyclovir | Acyclovir | 47 | 19 |
| Azithromycin | Azithromycin | 47 | 44 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Baclofen | Baclofen | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | 19 |
| Clonidine Hcl | Clonidine Hcl | 39 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 33 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 22 |
| Prolia | Denosumab | 36 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Methylprednisolone | Methylprednisolone | 34 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Folic Acid | Folic Acid | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 18 |
| Temazepam | Temazepam | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Propranolol Hcl | Propranolol Hcl | 28 | 12 |
| Valsartan | Valsartan | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Premarin | Estrogens, Conjugated | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Ibuprofen | Ibuprofen | 25 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Nystatin | Nystatin | 25 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 13 |
| Clonidine | Clonidine | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 20 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | 12 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Yuvafem | Estradiol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Ramipril | Ramipril | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 11 |
| Risperidone | Risperidone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $408.54 · 20 records | Amgen Inc. | ABRYSVO, COMIRNATY, EVENITY, FANAPT, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NP Thyroid 60, OTEZLA, PREVNAR 20, PROLIA, REPATHA, Respiratory, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error